Aspartame and the Increased Risks of Lymphoma Cancer

According to the findings of a recent study conducted by the Cancer Research Center of the European Foundation of Oncology and Environmental Sciences in Bologna, Italy, the frequent use of aspartame considerably increases the risks of developing lymphoma cancers and leukemia. Although the long-term study was conducted exclusively on female rats, without involving the active participation of any human subjects, the results are still very conclusive: aspartame is a clear carcinogenic agent that has a major contribution in the occurrence and evolution of lymphoma. A very popular chemical sweetener used as a replacement for sugar-based sweeteners, aspartame is no longer considered to be harmless.

The Italian research team that has conducted the study on the effects of aspartame on long-term use has stated that this chemical sweetener should be completely withdrawn from the market, as it greatly increases the risks of cancerous diseases. In present, aspartame is extensively used worldwide, being a common chemical component of chewing gum, sweet beverages and a wide range of other products.

Another series of studies have confirmed the strong carcinogenic potential of aspartame, revealing the fact that the chemical actually damages DNA, increasing the risks of cancer and degenerative brain diseases on long-term use. According to the findings, this commonly used product facilitates the development of tumors at various levels of the body, being a serious risk factor for brain cancers. The theories on the pronounced carcinogenic potential of aspartame have been recently supported by statistic reports: the incidence of brain tumors among animals exposed to prolonged doses of aspartame has increased over 47 times. The strong carcinogenic character of aspartame is due to the variety of toxins it contains. Medical scientists have stated that aspartame was also known to be a very unsafe chemical in the past; despite this fact, aspartame has been further promoted as harmless for commercial reasons.

The continuously increasing incidence of brain cancers among the global population is also considered to be related with the frequent use of aspartame-based products. Oncologists have stated that nowadays the incidence of brain tumors is considerably higher than it was a few decades ago, before aspartame products became available on the market. Furthermore, the increased frequency of various rare lymphoma subtypes such as reticulum cell sarcoma, microglioma and histiocytic lymphoma in the last few years has also been influenced by the use of aspartame.

Although exposure to aspartame can be considered a serious risk factor of lymphoma and other similar malignant diseases, the exact way aspartame triggers the occurrence of such disorders is still unknown. It is believed that aspartame directly interferes in the genetic structure of the body, causing genetic anomalies that later lead to production of cancerous cells. However, further studies are needed in order to provide cancer specialists with additional data on aspartame and its malignant effects on the human body.

So, if you want to find out more about symptoms of lymphoma or even about lymphoma cancer please visit this link http://www.lymphoma-center.com

This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.

Under-Treatment of Lymphoma and the Risks of Relapse

The treatment of lymphoma comprises a wide variety of immunosuppressant medications as well as a series of specific cancer therapies. Patients with lymphoma are often prescribed combination treatments, receiving carefully established doses of cancer medications according to age, gender and more important, the type of lymphoma and its stage of progression. In order to maximize the potency of the treatment and reduce the risks of relapse, doctors need to take in consideration all these previously mentioned aspects when deciding upon the appropriate dose of medications.

If patients are administered lymphoma medications in the wrong dose, the treatment will either fail to accomplish its expected action (in case of under-dosage) or generate severe temporary or even permanent side-effects (in case of over-dosage). Choosing the most appropriate drugs and deciding the perfect individual dose for each patient with lymphoma is a very challenging and time-consuming task for doctors. However, if this protocol is not followed correctly, the existing treatment of lymphoma can produce a series of undesired results.

Recent medical studies have revealed that the under-treatment of lymphoma is a very common phenomenon in hospitals, clinics and other medical establishments nationwide. Under-treatment of lymphoma has been recently identified as a significant cause of relapse among lymphoma sufferers. Due to the fact that repeated treatments often fail to control the progression of lymphoma in relapsed cases, it is very important to establish the appropriate dose of medications and decide upon the right duration of the specific treatment in the first place. Although the doses of lymphoma medications can be slightly adjusted over the period of administration, under-treatment of lymphoma should be avoided at all costs.

According to oncologists, patients who suffer from aggressively progressing Non-Hodgkin's Lymphoma should receive the specific chemotherapeutic treatment in precise doses and without delay in order to prevent relapse. Although rapidly progressing Non-Hodgkin's Lymphoma is considered to a severe, life-threatening disease, the existing forms of treatment and therapies can successfully reverse the malignant effects of the lymphoma cancer on the body and slow down the progression rate of the disease.

Paradoxically, fast progressing Non-Hodgkin's Lymphoma subtypes, as well as Hodgkin's Disease are more curable than slower progressing lymphomas. The phenomenon is explained by the increased potency of existing chemotherapeutical drugs in fighting against rapidly dividing malignant cells. However, despite the high curability of these varieties of lymphoma, it is imperative to prescribe the specific course of treatment in the right doses in order to obtain the best results. If the treatment is delayed, prematurely stopped or prescribed in the wrong doses, the risks of relapse are considerably increased and the afflicted patients rarely respond to re-treatment.

Recent studies conducted in randomly chosen medical establishments nationwide have revealed very disturbing facts regarding the treatment of lymphoma patients: around 50 percent of patients with highly curable forms of lymphoma cancers receive considerable dose reductions during chemotherapy. Thus, the chances of long-term survival for this category of patients are substantially reduced, despite the curable nature of their disease. Researchers have stated that it is imperative for cancer specialists to avoid under-treatment for patients with curable forms of lymphoma and that future treatments should be optimized in order to minimize the risks of relapse.

The initially decided doses of medications shouldn't be reduced unless the patients with lymphoma are confronted with severe side-effects. According to medical researchers, less than 5 percent of all lymphoma cases actually require ulterior changes in dosage; the other 95 percent of cases should receive the specific treatment in the same dose until the disease is completely overcome.

So, if you want to find out more about cutaneous t cell lymphoma or even about cutaneous t cell lymphoma please visit this link http://www.lymphoma-center.com/

This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.